Trial Profile
Evaluation of the Effectiveness and Safety of Monoclonal Antibody HR3(Nimotuzumab)for the treatment of patients with glial tumors of high grade malignancy.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 11 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by Cuban Clinical Trial Registry.
- 13 Sep 2011 New trial record